Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Treatment complications and lymphoedema

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Sepsis, thrombosis or cardiopulmonary toxicity

A hot rapidly swollen limb with systemic illness, sudden cyanotic arm swelling, fever during chemotherapy, acute dyspnoea, syncope or new heart failure may represent cellulitis, upper-extremity DVT, neutropenic sepsis, embolism or treatment-related cardiac or lung injury.

Action: Use ABCDE assessment, send cultures and blood tests, start time-critical antibiotics or anticoagulation when indicated, obtain urgent venous or cardiopulmonary imaging and involve acute oncology and the breast team; do not label an acute unilateral swollen arm as routine lymphoedema before excluding dangerous alternatives.

Synopsis

Recognise acute and late breast-treatment toxicity, diagnose arm or breast lymphoedema without missing thrombosis or recurrence and deliver early compression, movement, skin, infection, pain and survivorship management.

  • Breast-treatment lymphoedema can affect arm, hand, breast, chest wall or trunk and may arise months or years after axillary surgery or nodal radiotherapy.
  • Key early symptoms are heaviness, tightness, transient swelling, jewellery or clothing change and reduced flexibility; visible enlargement may appear only after a reversible phase.
  • Diagnosis is primarily clinical with standardised circumference, volume or bioimpedance assessment. Acute or atypical swelling requires venous thrombosis, infection and recurrence exclusion first.
  • First-line long-term management combines specialist-fitted compression, progressive exercise, weight support, skin care, self-management education and treatment of shoulder or scar dysfunction.
  • Complex decongestive therapy adds multilayer bandaging and manual lymphatic drainage in selected patients; massage alone without compression and movement is not a complete treatment.
  • Diuretics do not remove interstitial protein and are not routine lymphoedema therapy; use them only for a separate fluid-overload indication.
  • Cellulitis in a lymphoedematous limb needs prompt antibiotics, often a longer course than uncomplicated skin infection, and prevention planning after recovery.
  • Necessary venepuncture, blood pressure or urgent treatment should not be withheld when no alternative exists; minimise avoidable skin trauma and use the other limb when practical.
  • Sentinel-node biopsy, early shoulder movement, weight optimisation, prompt infection treatment and surveillance reduce morbidity but cannot guarantee prevention.
  • Investigate new or rapidly progressive swelling, hard nodes or neuropathic pain for recurrence even when lymphoedema has been stable for years.
  • Review cardiac, pulmonary, bone, menopausal, neuropathic, cognitive and sexual toxicity systematically rather than treating survivorship as cancer-free only.
  • Selected refractory disease may benefit from lymphovenous bypass, vascularised node transfer or liposuction after expert imaging and optimisation, but compression often remains necessary.

Key red flags

Fever, rigors, spreading erythema, severe pain, hypotension or confusion in a lymphoedematous limb suggests cellulitis with possible sepsis.

Abrupt arm and neck swelling, cyanosis, venous distension, line dysfunction or pleuritic symptoms raises upper-extremity thrombosis or central venous obstruction.

A new hard axillary or supraclavicular mass, progressive pain, brachial-plexus signs or rapidly worsening oedema can indicate locoregional recurrence.

New breathlessness, dry cough or infiltrates after radiotherapy, chemotherapy, immunotherapy or antibody–drug conjugate requires differentiation of pneumonitis, infection, embolism and progression.

Orthopnoea, oedema, chest pain, arrhythmia or reduced exercise tolerance after anthracycline or HER2 treatment requires prompt cardiac evaluation.

A tense postoperative breast, falling blood pressure, severe pain or flap colour change suggests haematoma or compromised reconstruction requiring urgent surgery.

Cellulitis

Rapid warmth, erythema, tenderness, fever, malaise and worsening swelling requires prompt antibiotic treatment and sepsis assessment.

Venous or central obstruction

Sudden cyanotic swelling, neck involvement, superficial collaterals or line dysfunction is atypical for uncomplicated chronic lymphoedema.

Investigation priorities

01
First-line standardised limb or breast measurementFirst stepFirst line

Confirm asymmetry, establish a baseline and track response using circumference, calculated volume, perometry or bioimpedance.

02
First-line venous duplex for acute arm swellingFirst line

Exclude axillary and upper-arm DVT when onset, pain, catheter or venous signs are atypical for chronic lymphoedema.

Management branches

New swellingExclude urgent mimics before compression

An arm, breast or chest wall becomes newly or rapidly swollen after breast-cancer treatment.

  1. Assess onset, fever, pain, colour, venous collaterals, catheter, nodes, respiratory symptoms and cancer history and compare both limbs and central venous territories.
  2. Obtain urgent duplex and central imaging for suspected thrombosis, antibiotics for cellulitis and cross-sectional imaging with biopsy for possible recurrence.
  3. When dangerous alternatives are excluded, document baseline volume and refer early to a lymphoedema service for an individual compression and rehabilitation plan.

Key medicines

Flucloxacillin for lymphoedema-associated cellulitisFor a stable adult with non-purulent cellulitis and no immediate penicillin allergy, a common lymphoedema regimen is flucloxacillin 500 mg orally four times daily for 14 days, adjusted to severity, culture and local guidance.Hospitalise and use intravenous therapy for systemic toxicity, rapid progression, neutropenia or oral failure; review at 48 hours, account for allergy and hepatic risk and do not confuse recurrence with infection.
Phenoxymethylpenicillin prophylaxisAfter recurrent proven cellulitis, a specialist protocol may use phenoxymethylpenicillin 250 mg orally twice daily, often 500 mg twice daily when BMI is 33 kg/m² or higher, with duration reviewed after at least 12 months.Confirm that episodes were cellulitis, review penicillin allergy, adherence and resistance and reassess need rather than prescribing indefinitely without lymphoedema optimisation.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG101 breast treatment complicationsAxillary treatment, lymphoedema information, rehabilitation and treatment monitoring.
  • NHS lymphoedema treatmentCompression, exercise, skin care and decongestive therapy.
  • Lymphoedema Support Network cellulitis guidanceCellulitis treatment and recurrent-infection prevention in lymphoedema.
  • NHS lymphoedema overviewPresentation, causes, diagnosis and complications.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom